Диссертация (1140650), страница 21
Текст из файла (страница 21)
21, №1. ‒ P. 37-45.162. Park S.I., Lee H.R., Kim S. et al. Time-sequential modulation inexpression of growth factors from platelet-rich plasma (PRP) on the chondrocytecultures // Mol Cell Biochem. ‒ 2012. ‒ Vol. 361, № 1-2. ‒ P. 9-17.163. Patel S., Dhillon M.S., Aggarwal S. et al. Treatment with platelet-richplasma is more effective than placebo for knee osteoarthritis: a prospective, doubleblind, randomized trial // Am J Sports Med. ‒ 2013. ‒ Vol. 41, № 2. ‒ P. 356-364.164. Peterson J.E., Zurakowski D., Italiano J.E., Jr.
et al. Normal ranges ofangiogenesis regulatory proteins in human platelets // Am J Hematol. ‒ 2010. ‒ Vol.85, № 7. ‒ P. 487-493.165. Pourcho A.M., Smith J., Wisniewski S.J. et al. Intraarticular plateletrich plasma injection in the treatment of knee osteoarthritis: review andrecommendations // Am J Phys Med Rehabil. ‒ 2014. ‒ Vol. 93, № 11 Suppl 3.
‒ P.S108-121.166. Pufe T., Lemke A., Kurz B. et al. Mechanical overload induces VEGFin cartilage discs via hypoxia-inducible factor // Am J Pathol. ‒ 2004. ‒ Vol. 164, №1. ‒ P. 185-192.167. Qi Y.Y., Chen X., Jiang Y.Z. et al. Local delivery of autologous plateletin collagen matrix simulated in situ articular cartilage repair // Cell Transplant. ‒2009. ‒ Vol. 18, № 10. ‒ P. 1161-1169.168. Raeissadat S.A., Rayegani S.M., Babaee M. et al. The effect of plateletrich plasma on pain, function, and quality of life of patients with knee osteoarthritis// Pain Res Treat.
‒ 2013. ‒ Vol. 2013. ‒ P. 165967.169. Raeissadat S.A., Rayegani S.M., Hassanabadi H. et al. KneeOsteoarthritis Injection Choices: Platelet- Rich Plasma (PRP) Versus Hyaluronic128Acid (A one-year randomized clinical trial) // Clin Med Insights ArthritisMusculoskelet Disord. ‒ 2015. ‒ Vol. 8. ‒ P. 1-8.170. Richmond J., Hunter D., Irrgang J. et al. American Academy ofOrthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis(OA) of the knee // J Bone Joint Surg Am. ‒ 2010.
‒ Vol. 92, № 4. ‒ P. 990-993.171. Rubio-Azpeitia E., Andia I. Partnership between platelet-rich plasmaand mesenchymal stem cells: in vitro experience // Muscles Ligaments Tendons J. ‒2014. ‒ Vol. 4, № 1. ‒ P. 52-62.172. Rutgers M., Saris D.B., Yang K.G. et al. Joint injury and osteoarthritis:soluble mediators in the course and treatment of cartilage pathology //Immunotherapy.
‒ 2009. ‒ Vol. 1, № 3. ‒ P. 435-445.173. Sampson S., Reed M., Silvers H. et al. Injection of platelet-rich plasmain patients with primary and secondary knee osteoarthritis: a pilot study // Am J PhysMed Rehabil. ‒ 2010. ‒ Vol. 89, № 12. ‒ P. 961-969.174. Sanchez M., Anitua E., Azofra J. et al. Intra-articular injection of anautologous preparation rich in growth factors for the treatment of knee OA: aretrospective cohort study // Clin Exp Rheumatol.
‒ 2008. ‒ Vol. 26, № 5. ‒ P. 910913.175. Sanchez M., Fiz N., Azofra J. et al. A randomized clinical trialevaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid inthe short-term treatment of symptomatic knee osteoarthritis // Arthroscopy. ‒ 2012.‒ Vol. 28, № 8. ‒ P. 1070-1078.176. Sanchez M., Guadilla J., Fiz N. et al. Ultrasound-guided platelet-richplasma injections for the treatment of osteoarthritis of the hip // Rheumatology(Oxford). ‒ 2012. ‒ Vol. 51, № 1. ‒ P. 144-150.177. Say F., Gurler D., Yener K. et al.
Platelet-rich plasma injection is moreeffective than hyaluronic acid in the treatment of knee osteoarthritis // Acta ChirOrthop Traumatol Cech. ‒ 2013. ‒ Vol. 80, № 4. ‒ P. 278-283.178. Scharstuhl A., Glansbeek H.L., van Beuningen H.M. et al. Inhibition ofendogenous TGF-beta during experimental osteoarthritis prevents osteophyte129formation and impairs cartilage repair // J Immunol.
‒ 2002. ‒ Vol. 169, № 1. ‒ P.507-514.179. Scheuerer B., Ernst M., Durrbaum-Landmann I. et al. The CXCchemokine platelet factor 4 promotes monocyte survival and induces monocytedifferentiation into macrophages // Blood. ‒ 2000. ‒ Vol. 95, № 4. ‒ P. 1158-1166.180. Sellam J., Berenbaum F. The role of synovitis in pathophysiology andclinical symptoms of osteoarthritis // Nat Rev Rheumatol. ‒ 2010. ‒ Vol. 6, № 11. ‒P.
625-635.181. Sheth U., Simunovic N., Klein G. et al. Efficacy of autologous plateletrich plasma use for orthopaedic indications: a meta-analysis // J Bone Joint Surg Am.‒ 2012. ‒ Vol. 94, № 4. ‒ P. 298-307.182. Smyth N.A., Murawski C.D., Fortier L.A. et al. Platelet-rich plasma inthe pathologic processes of cartilage: review of basic science evidence //Arthroscopy. – 2013. – Vol.
29. – P.1399–1409.183. Sofat N. Analysing the role of endogenous matrix molecules in thedevelopment of osteoarthritis // Int J Exp Pathol. ‒ 2009. ‒ Vol. 90, № 5. ‒ P. 463479.184. Sorokin L. The impact of the extracellular matrix on inflammation //Nat Rev Immunol. ‒ 2010. ‒ Vol. 10, № 10. ‒ P. 712-723.185. Spakova T., Rosocha J., Lacko M. et al. Treatment of knee jointosteoarthritis with autologous platelet-rich plasma in comparison with hyaluronicacid // Am J Phys Med Rehabil. ‒ 2012. ‒ Vol. 91, № 5.
‒ P. 411-417.186. Spreafico A., Chellini F., Frediani B. et al. Biochemical investigationof the effects of human platelet releasates on human articular chondrocytes // J CellBiochem. ‒ 2009. ‒ Vol. 108, № 5. ‒ P. 1153-1165.187. Sun Y., Feng Y., Zhang C.Q.
et al. The regenerative effect of plateletrich plasma on healing in large osteochondral defects // Int Orthop. ‒ 2010. ‒ Vol.34, № 4. ‒ P. 589-97.130188. Sundman E.A., Cole B.J., Fortier L.A. Growth factor and cataboliccytokine concentrations are influenced by the cellular composition of platelet-richplasma // Am J Sports Med. ‒ 2011. ‒ Vol.
39, № 10. ‒ P. 2135-2140.189. Sundman E.A., Cole B.J., Karas V. et al. The anti-inflammatory andmatrix restorative mechanisms of platelet-rich plasma in osteoarthritis // Am J SportsMed. ‒ 2014. ‒ Vol. 42, № 1. ‒ P. 35-41.190. Taylor D.W., Petrera M., Hendry M. et al. A systematic review of theuse of platelet-rich plasma in sports medicine as a new treatment for tendon andligament injuries // Clin J Sport Med.
‒ 2011. ‒ Vol. 21, № 4. ‒ P. 344-352.191. Thon J.N., Italiano J.E. Platelets: production, morphology andultrastructure // Handb Exp Pharmacol. ‒ 2012. ‒ № 210. ‒ P. 3-22.192. Tietze D.C., Geissler K., Borchers J. The effects of platelet-rich plasmain the treatment of large-joint osteoarthritis: a systematic review // Phys Sportsmed.‒ 2014. ‒ Vol. 42, № 2. ‒ P. 27-37.193.
Tohidnezhad M., Varoga D., Wruck C.J. et al. Platelets display potentantimicrobial activity and release human beta-defensin 2 // Platelets. ‒ 2012. ‒ Vol.23, № 3. ‒ P. 217-223.194. van Buul G.M., Koevoet W.L., Kops N. et al. Platelet-rich plasmareleasate inhibits inflammatory processes in osteoarthritic chondrocytes // Am JSports Med. ‒ 2011. ‒ Vol. 39, № 11. ‒ P. 2362-2370.195. vandenBergW.B.Osteoarthritisyear2010inreview:pathomechanisms // Osteoarthritis Cartilage.
‒ 2011. ‒ Vol. 19, № 4. ‒ P. 338-341.196. van der Kraan P.M., Goumans M.J., Blaney Davidson E. et al. Agedependent alteration of TGF-beta signalling in osteoarthritis // Cell Tissue Res. ‒2012. ‒ Vol. 347, № 1. ‒ P. 257-265.197. Vaquerizo V., Plasencia M.A., Arribas I. et al. Comparison of intraarticular injections of plasma rich in growth factors (PRGF-Endoret) versusDurolane hyaluronic acid in the treatment of patients with symptomaticosteoarthritis: a randomized controlled trial // Arthroscopy.
‒ 2013. ‒ Vol. 29, № 10.‒ P. 1635-1643.131198. Walsh E.M., Kim R., Del Valle L. et al. Importance of interactionbetween nerve growth factor and alpha9beta1 integrin in glial tumor angiogenesis //Neuro Oncol. ‒ 2012. ‒ Vol. 14, № 7. ‒ P. 890-901.199. Walshe T.E., Dole V.S., Maharaj A.S. et al.
Inhibition of VEGF orTGF-beta signaling activates endothelium and increases leukocyte rolling //Arterioscler Thromb Vasc Biol. ‒ 2009. ‒ Vol. 29, № 8. ‒ P. 1185-1192.200. Walshe T.E., Saint-Geniez M., Maharaj A.S. et al. TGF-beta is requiredfor vascular barrier function, endothelial survival and homeostasis of the adultmicrovasculature // PLoS One. ‒ 2009. ‒ Vol. 4, № 4. ‒ P. 5149.201. Wang-Saegusa A., Cugat R., Ares O. et al. Infiltration of plasma rich ingrowth factors for osteoarthritis of the knee short-term effects on function andquality of life // Arch Orthop Trauma Surg.
‒ 2011. ‒ Vol. 131, № 3. ‒ P. 311-317.202. Wiegant K., van Roermund P.M., Intema F. et al. Sustained clinical andstructural benefit after joint distraction in the treatment of severe knee osteoarthritis// Osteoarthritis Cartilage. ‒ 2013. ‒ Vol. 21, № 11. ‒ P.
1660-1667.203. Woodell-May J., Matuska A., Oyster M. et al. Autologous proteinsolution inhibits MMP-13 production by IL-1beta and TNFalpha-stimulated humanarticular chondrocytes // J Orthop Res. ‒ 2011. ‒ Vol. 29, № 9. ‒ P. 1320-1326.204. Xie X., Zhang C., Tuan R.S. Biology of platelet-rich plasma and itsclinical application in cartilage repair // Arthritis Res Ther. ‒ 2014. ‒ Vol. 16, № 1.‒ P.
204.205. Yamada Y., Nakamura S., Ueda M. et al. Papilla regeneration byinjectable stem cell therapy with regenerative medicine: long-term clinical prognosis// J Tissue Eng Regen Med. ‒ 2015. ‒ Vol. 9, № 3. ‒ P. 305-309.206. Zhang W., Nuki G., Moskowitz R.W. et al. OARSI recommendationsfor the management of hip and knee osteoarthritis: part III: Changes in evidencefollowing systematic cumulative update of research published through January 2009// Osteoarthritis Cartilage. ‒ 2010. ‒ Vol. 18, № 4. ‒ P. 476-499.132207.
Zhu Y., Yuan M., Meng H.Y. et al. Basic science and clinicalapplication of platelet-rich plasma for cartilage defects and osteoarthritis: a review// Osteoarthritis Cartilage. ‒ 2013. ‒ Vol. 21, № 11. ‒ P. 1627-1637.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
